Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Subscribe To Our Newsletter & Stay Updated
